Tolga Tanguler Sells 1,959 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,959 shares of the company’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $607,446.72. Following the sale, the executive vice president owned 31,769 shares of the company’s stock, valued at $9,850,931.52. The trade was a 5.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Tolga Tanguler also recently made the following trade(s):

• On Monday, January 12th, Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Trading Up 5.8%

Shares of NASDAQ:ALNY traded up $18.21 during mid-day trading on Tuesday, reaching $332.61. The stock had a trading volume of 1,516,365 shares, compared to its average volume of 1,632,567. The firm has a 50 day simple moving average of $372.67 and a two-hundred day simple moving average of $424.73. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $495.55. The firm has a market cap of $44.11 billion, a PE ratio of 194.51 and a beta of 0.35. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. During the same quarter last year, the business posted ($0.65) earnings per share. The company’s revenue for the quarter was up 84.9% on a year-over-year basis. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. OFI Invest Asset Management increased its stake in shares of Alnylam Pharmaceuticals by 5.8% during the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 22 shares during the last quarter. Howard Capital Management Inc. raised its stake in Alnylam Pharmaceuticals by 2.9% in the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after buying an additional 24 shares during the period. Frank Rimerman Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after buying an additional 24 shares during the last quarter. Coastal Bridge Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 2.3% during the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after acquiring an additional 25 shares during the period. Finally, Meridian Financial Advisors LLC raised its stake in Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after acquiring an additional 28 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

ALNY has been the topic of several research analyst reports. Leerink Partners dropped their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Bank of America reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Finally, Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.